• Mashup Score: 2
    Protypia - 18 hour(s) ago

    Protypia was founded in 2017 by Dan Liebler to bring emerging mass spectrometry (MS) proteomics technology to oncology therapeutic discovery and development. Protypia also works with leading academic collaborators to advance the application of MS protein analysis to identify therapeutic targets and protein features that govern drug resistance and response. Protypia is now part of Inotiv, a leading contract research organization specializing in nonclinical and analytical drug dis covery and development

    Tweet Tweets with this article
    • Thanks to funders @PrecisionOncIre @helpinghollesst thanks to @UCDClinRes @sysbioire @UCDMedicine for support and collaborators at Protypia (https://t.co/hGiSdsTWaQ) and all our co-authors @MaterCancer @Isgoppi